Barrington lowered the firm’s price target on Haemonetics to $105 from $114 and keeps an Outperform rating on the shares post the earnings report. The analyst cites macro concerns for the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HAE:
- Haemonetics raises FY24 adjusted EPS view to $3.75-$3.95 from $3.60-$3.90
- Haemonetics reports Q2 adjusted EPS 99c, consensus 89c
- Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- HAE Upcoming Earnings Report: What to Expect?
- Opsens downgraded to Market Perform from Outperform at Raymond James
